

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Results from the Phase III BRUIN CLL-313 study evaluating first-line pirtobrutinib versus bendamustine/rituximab for patients with treatment-naïve chronic lymphocytic leukemia (CLL) included which efficacy finding?**
 - a. No significant difference in progression-free survival (PFS)
 - b. A numerical but nonsignificant improvement in PFS with pirtobrutinib
 - c. A statistically significant improvement in PFS with pirtobrutinib**
- 2. Results from the Phase III BRUIN CLL-314 study evaluating pirtobrutinib versus ibrutinib demonstrated which PFS outcome in the population of patients with treatment-naïve CLL?**
 - a. Pirtobrutinib reduced the risk of disease progression or death by 23%
 - b. Pirtobrutinib reduced the risk of disease progression or death by 76%**
 - c. Pirtobrutinib did not reduce the risk of disease progression or death
- 3. Compared to complete response results from the TRANSCEND CLL 004 trial, the complete response rate observed in a real-world analysis of lisocabtagene maraleucel for patients with CLL/small lymphocytic lymphoma was ...**
 - a. Lower
 - b. Higher**
 - c. Similar
- 4. Six-year follow-up data from the Phase III SEQUOIA trial demonstrated which PFS outcome in arm C, evaluating zanubrutinib for treatment-naïve del(17p) CLL?**
 - a. Six-year PFS rate of 16%
 - b. Six-year PFS rate of 32%
 - c. Six-year PFS rate of 64%**
- 5. Which of the following drug types best reflects the mechanism of action of BGB-16673?**
 - a. Bcl-2 inhibitor
 - b. PI3K inhibitor
 - c. Bruton tyrosine kinase degrader**